Kum Kum Khanna

9PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targetsPredictive and prognostic markersCancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 03, 2025
Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Prahlad V Raninga, Bijun Zeng, Davide Moi

|Dec 20, 2024
CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Prahlad V Raninga, Bijun Zeng, Davide Moi

|Oct 28, 2021
Cep55 regulation of PI3K/Akt signaling is required for neocortical development and ciliogenesis.

Behnam Rashidieh, Belal Shohayeb, Amanda Louise Bain

|Aug 07, 2021
Targeting BRF2 in Cancer Using Repurposed Drugs.

Behnam Rashidieh, Maryam Molakarimi, Ammar Mohseni

|Jul 20, 2021
Differential Regulation of Lacto-/Neolacto- Glycosphingolipid Biosynthesis Pathway Reveals Transcription Factors as Potential Candidates in Triple-Negative Breast Cancer.

Ruichao Zeng, Ahmed Mohamed, Kum Kum Khanna

|Jun 02, 2021
CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer.

Ashwini Makhale, Devathri Nanayakkara, Prahlad Raninga

Pageof 2

Frequent Collaborators

4 joint publications

Murugan Kalimutho

2 joint publications

Behnam Rashidieh

2 joint publications

Rachael C Adams

2 joint publications

Chelsea Mayoh